Observational studyCanadian respiratory journal2016
Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count).
Observational study in Canadian respiratory journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Diagnostic accuracy of the cancer ratio for the prediction of malignant pleural effusion: evidence from a validation study and meta-analysis.Annals of medicine · 2021Pooled it
- Diagnostic value of biochemical ratios in the differential diagnosis of tuberculous and malignant pleural effusions.BMC pulmonary medicine · 2026Article
- The cancer ratio plus in the differential diagnosis of pleural effusions: a scoping review of current evidence.Biochemia medica · 2026Article
- Development of a scoring system based on a nomogram to identify malignant pleural effusion.Journal of thoracic disease · 2025Article
- Case Report: Rare pleural effusion-a case of B-lymphoblastic lymphoma presenting with pleural effusion and diagnostic challenges.Frontiers in medicine · 2025Article
- The Use of "Cancer Ratio" in Differentiating Malignant and Tuberculous Pleural Effusions: Protocol for a Prospective Observational Study.JMIR research protocols · 2024Observational
- LDH/ADA ratio in pleural fluid for the diagnosis of infectious pleurisy.Clinical and experimental medicine · 2023Article
- Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma.Translational lung cancer research · 2023Article
- Age affects the diagnostic accuracy of the cancer ratio for malignant pleural effusion.BMC pulmonary medicine · 2023Article
- Differentiating between tuberculous and non-tuberculous pleural effusions using the pleural fluid ratio of 10× adenosine deaminase/lactate dehydrogenase.Journal of thoracic disease · 2023Article
- Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis.Cancer cell international · 2022Review
- Developing a Prediction Score for the Diagnosis of Malignant Pleural Effusion: MPE Score.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- GC-MS metabolomics identifies novel biomarkers to distinguish tuberculosis pleural effusion from malignant pleural effusion.Journal of clinical laboratory analysis · 2021Article
- Article
- Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review.Translational lung cancer research · 2021Review
- Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram.Frontiers in oncology · 2021Article
- Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion.Clinics (Sao Paulo, Brazil) · 2021Article
- Diagnostic accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis.Annals of translational medicine · 2019Article
- Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.